Low-dose recombinant canine interferon-γ for treatment of canine atopic dermatitis: An open randomized comparative trial of two doses

Abstract

The purpose of this study was to investigate the minimum effective dose of recombinant canine interferon-gamma (rCaIFN-gamma) for the treatment of dogs with atopic dermatitis (AD). Thirty-four dogs with AD from 17 animal hospitals in Japan were administered half or one-fifth of the approved rCaIFN-gamma dose of 10 000 units/kg, three times a week for 4 weeks, followed by once weekly for an additional 4 weeks. Pruritus, excoriation, erythema and alopecia were evaluated and scored by the investigators on weeks 2, 4, 6, 8 and 12. The efficacy rate (number of excellent cases + number of good cases/total number of cases) at week 8 in the 2000 units/kg group was 36.4% for pruritus, 36.4% for excoriation, 45.5% for erythema and 36.4% for alopecia. In contrast, in the 5000 units/kg group, the efficacy rate was 64.3% for pruritus, 57.1% for excoriation, 78.6% for erythema and 78.6% for alopecia. The efficacy rate of the 5000 units/kg group was high for all signs evaluated and comparable to that of the 10 000 units/kg group reported in a previous study. The results of this study showed that 2000 units/kg of rCaIFN-gamma is less effective than 5000 units/kg to treat dogs with AD, and the efficacy of the 5000 units/kg dose is comparable to that of 10 000 units/kg at week 8.

Th17-skewed immune response and cluster of differentiation 40 ligand expression in canine steroid-responsive meningitis-arteritis, a large animal model for neutrophilic meningitis

“…Current medical trials aimed to neutralize IL-17 or IL-23 have shown to be highly effective in humans in the treatment of psoriasis and show promising initial results in ankylosing spondylitis and multiple sclerosis [65]. These innovating therapies are now appearing in companion animal medicine [66] and should be considered in inflammatory autoimmune diseases like SRMA.…”

Expression of Interferon Gamma by a Recombinant Rabies Virus Strongly Attenuates the Pathogenicity of the Virus via Induction of Type I Interferon

“…It has been tested experimentally as an adjuvant in vaccines (20,21) and as a treatment in animal models of disease, such as tuberculosis (22), each with various degrees of success. Currently the only FDA-approved uses for IFN-␥ in humans are treatments for chronic granulomatous disease (23) and osteopetrosis (24), but IFN-␥ is also prescribed by veterinarians to treat canine atopic dermatitis (25). These clinical uses of IFN-␥ highlight its pleiotropic nature as the mechanisms of action in these diseases are through enhanced innate immunity, activation of osteoclasts, and suppression of the adaptive immune response, respectively.…”

The effects of a topical lipid complex therapy on dogs with atopic dermatitis: a double blind, randomized, placebo‐controlled study

“…There are many treatment options available to practitioners for CAD including topical and systemic fatty acids . Polyunsaturated fatty acids have been shown to not only improve the skin barrier, but also decrease skin inflammation .…”

“…There are many treatment options available to practitioners for CAD including topical and systemic fatty acids. 1,12,14,[23][24][25][26][27] Polyunsaturated fatty acids have been shown to not only improve the skin barrier, but also decrease skin inflammation. 12,13,22,28 Thus, a topical product containing those agents may improve clinical signs and reduce the need for more potent medications.…”